GMFM 1 year after continuous intrathecal baclofen infusion

Area of Science:

• Neurology
• Pediatrics
• Rehabilitation Medicine

Background:

• Cerebral palsy (CP) is a group of disorders affecting movement and posture, often characterized by increased muscle tone (spasticity).
• Intrathecal baclofen infusion (ITB) is a treatment option for severe spasticity in CP, aiming to improve motor function and quality of life.

Purpose of the Study:

• To evaluate the effectiveness of continuous intrathecal baclofen infusion in improving motor function in individuals with cerebral palsy.
• To assess changes in muscle tone and perceived functional improvements following ITB therapy.

Main Methods:

• A prospective, open-label, multi-center case series involving 31 subjects with CP aged 4-29 years.
• Participants had pre-treatment lower extremity Ashworth scores of ≥3 and received an implanted pump for continuous ITB.
• Motor function was assessed using the Gross Motor Function Measure (GMFM) before and 1 year after pump implantation.

Main Results:

• Significant improvements in mean GMFM scores were observed in younger age groups (<8 years and 8-18 years) and in CP Classes 2 and 5.
• A statistically significant decrease in Ashworth scores (muscle tone) was noted across CP Classes 2-5.
• Subjects and caregivers reported improvements in motor control, positioning, and endurance.

Conclusions:

• Continuous intrathecal baclofen infusion is an effective treatment for improving motor function and reducing spasticity in select individuals with cerebral palsy.
• ITB therapy offers functional benefits, including enhanced motor control, positioning, and endurance, contributing to improved quality of life.